AKT1 and prostate cancer: These observations are in agreement with recent studies indicating that reactive oxygen species 41 or geldanamycin, an agent proposed for clinical testing in malignant melanoma, breast and prostate cancer 42,43, act by inducing AKT dephosphorylation and degradation.